Nanosomal Docetaxel Lipid Suspension in Treating Patients With Advanced Solid Tumors - Trial NCT01957995
Access comprehensive clinical trial information for NCT01957995 through Pure Global AI's free database. This Phase 1 trial is sponsored by University of Southern California and is currently Completed. The study focuses on Unspecified Adult Solid Tumor, Protocol Specific. Target enrollment is 13 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
nanosomal docetaxel lipid suspension
Interventional
drug
Sponsor & Location
University of Southern California
Timeline & Enrollment
Phase 1
Nov 08, 2013
Jul 14, 2016
Primary Outcome
Pharmacokinetic profile of nanosomal docetaxel lipid suspension
Summary
This randomized phase I trial studies the side effects and best dose of nanosomal docetaxel
 lipid suspension in treating patients with advanced solid tumors. Drugs used in chemotherapy,
 such as nanosomal docetaxel lipid suspension, work in different ways to stop the growth of
 tumor cells, either by killing the cells or by stopping them from dividing.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT01957995
Non-Device Trial